CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/27/2022
Back to search
Official data from USPTO
NOJECTION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
10/28/2022
Trademark type
Word
Nice classes
5
Filing date
01/10/2018
Registration date
09/07/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/07/2021
Last transaction
10/28/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/18/2021
First use in commerce
06/18/2021
Drawing code
4
Owner type
99
Owner location
Ringaskiddy, IE
Examiner
KAJUBI, ELIZABETH
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
B. D. (pessoa física)
B. D. (pessoa física)
Biohaven Pharmaceutical Holding Company Limited
Representatives
Andrea Christensen Pfizer Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicated and pharmaceutical preparationsboth prescription and over-the-counterfor use in connection with humans and animalsfor the treatment of central nervous system disordersneurologic illnessespsychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemiapost-stroke recoverysevere intracranial atherosclerosiscarotid endarterectomycardiac bypasscerebral vasculitisreversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuriespost- intracranial hemorrhage recoverytraumatic brain injuryspinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's disease (AD)Amyotrophic Lateral Sclerosis (ALS)Huntington's diseaseLewy body dementiafrontotemporal dementiavascular dementiaParkinson's diseasecognitive impairment of agingprogressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathiesglaucomadiabetic retinopathyischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of painopioid sparing analgesiacancer painchronic neuropathic painperipheral neuropathylow back pain in the nature of failed back surgery syndromeradiculopathy in the nature of sciaticadiabetic peripheral neuropathypost-herpetic neuralgiachemotherapy induced neuropathy and other medication induced neuropathiescomplex regional pain syndromefibromyalgiachronic post-operative paincluster thoracotomyphantom limbstump neuroma; pharmaceutical preparations for the treatment of headache and facial painheadachemigrainechronic daily headachecluster headachetrigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseasesbreath holding in Rett syndromedystoniasdysphagiagait abnormalitiesbulbar function in ALSpseudobulbar affectlevodopa-induced dyskinesias in Parkinson's diseaseagitation in ADdisinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsyprecision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorderstreatment resistant depressionPost Traumatic Stress Disorder (PTSD) in the nature of hyperarousalsubstance abuse disordersaddiction disordersObsessive Compulsive Disorder (OCD)hoardingtrichotillomaniaeating disordersGeneralized Anxiety Disorder (GAD)adjustment disorderspanic disordermajor depressive episodebipolar disorder in the nature of manic and depressive episodesdysthymiacyclothymiapsychotic disordersschizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disordersspinocerebellar ataxiaFriedriech's ataxiamultisystem atrophyessential tremor; pharmaceutical preparations for the treatment of hearing disorderstinnitusdeliriumsleep disordersparasomniaslearning disordersAttention Deficit Disorder (ADD)Pervasive Developmental Disorders (PDD)Asperger's syndromeautismmenopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancermonotherapy and adjunctive use
Publications
History of USPTO decisions and trademark events.
43 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/27/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/27/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/27/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/07/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/04/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/03/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/27/2021
IUAF
USE AMENDMENT FILED
06/24/2021
EISU
TEAS STATEMENT OF USE RECEIVED
06/24/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/24/2020
EX5G
SOU EXTENSION 5 GRANTED
12/23/2020
EXT5
SOU EXTENSION 5 FILED
12/21/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/21/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/19/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/01/2020
EX4G
SOU EXTENSION 4 GRANTED
06/30/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/30/2020
EXT4
SOU EXTENSION 4 FILED
06/17/2020
EEXT
SOU TEAS EXTENSION RECEIVED
06/17/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/21/2019
EX3G
SOU EXTENSION 3 GRANTED
12/19/2019
EXT3
SOU EXTENSION 3 FILED
12/19/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/19/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/23/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/23/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/25/2019
EX2G
SOU EXTENSION 2 GRANTED
06/21/2019
EXT2
SOU EXTENSION 2 FILED
06/21/2019
EEXT
SOU TEAS EXTENSION RECEIVED
06/21/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/12/2018
EX1G
SOU EXTENSION 1 GRANTED
09/10/2018
EXT1
SOU EXTENSION 1 FILED
09/10/2018
EEXT
SOU TEAS EXTENSION RECEIVED
09/10/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/26/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/01/2018
PUBO
PUBLISHED FOR OPPOSITION
05/01/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/11/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/27/2018
DOCK
ASSIGNED TO EXAMINER
03/27/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/24/2018
NWAP
NEW APPLICATION ENTERED
01/13/2018
Continuous trademark protection
Get notified about every new filing that threatens NOJECTION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.